
Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary

Glennie JL

Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1997

Authors' objectives

To carry out a comparative therapeutic and economic evaluation of a) clozapine in treatment-resistant schizophrenic patients or those suffering from debilitating adverse effects from conventional phenothiazines; and of b) risperidone as first line therapy for patients with schizophrenia, and in patients suffering from adverse effects from phenothiazines.

Project page URL

<https://www.ccohta.ca/>

Link to NHS EED abstract

<http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=21997008319>

Indexing Status

Subject indexing assigned by CRD

MeSH

Clozapine /therapeutic use; Risperidone /therapeutic use; Schizophrenia /drug therapy

Language Published

English, French

Country of organisation

Canada

Address for correspondence

600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392; Email: jills@ccohta.ca

AccessionNumber

31997008258

Date bibliographic record published

31/10/1997

Date abstract record published

31/10/1997